Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ana de Vera"'
Autor:
Jerry Bagel, John Nia, Peter W. Hashim, Manmath Patekar, Ana de Vera, Sophie Hugot, Kuan Sheng, Summer Xia, Isabelle Gilloteau, Elisa Muscianisi, Andrew Blauvelt, Mark Lebwohl
Publikováno v:
Dermatology and Therapy, Vol 8, Iss 4, Pp 571-579 (2018)
Abstract Introduction Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated superior efficacy to ustekinumab in the phase 3b CLEAR study of moderate to severe plaque psoriasis. Here, we report 16-week results from CLAR
Externí odkaz:
https://doaj.org/article/ff7214469fd740c1a9a96f89a5b1b2e5
Autor:
Elisa Muscianisi, Isabelle Gilloteau, Mark Lebwohl, Andrew Blauvelt, John K Nia, Sophie Hugot, Jerry Bagel, Summer Xia, Manmath Patekar, Ana de Vera, Kuan Sheng, Peter W Hashim
Publikováno v:
Dermatology and Therapy
Dermatology and Therapy, Vol 8, Iss 4, Pp 571-579 (2018)
Dermatology and Therapy, Vol 8, Iss 4, Pp 571-579 (2018)
Introduction Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has demonstrated superior efficacy to ustekinumab in the phase 3b CLEAR study of moderate to severe plaque psoriasis. Here, we report 16-week results from CLARITY, a se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4536a28939455d82a60e00780380727
https://doi.org/10.1007/s13555-018-0265-y
https://doi.org/10.1007/s13555-018-0265-y
Autor:
V Risson, Gorana Capkun, Harsh Sharma, Billy Amzal, Thomas Obadia, Shubhro Ghosh, Ana de Vera, Jens Schmidt
Publikováno v:
Theoretical Biology and Medical Modelling
Theoretical Biology and Medical Modelling, BioMed Central, 2019, 16 (1), pp.17. ⟨10.1186/s12976-019-0114-4⟩
Theoretical Biology and Medical Modelling, Vol 16, Iss 1, Pp 1-10 (2019)
Theoretical Biology & Medical Modelling
Theoretical Biology and Medical Modelling, BioMed Central, 2019, 16 (1), pp.17. ⟨10.1186/s12976-019-0114-4⟩
Theoretical Biology and Medical Modelling, Vol 16, Iss 1, Pp 1-10 (2019)
Theoretical Biology & Medical Modelling
Background Associations between disease characteristics and payer-relevant outcomes can be difficult to establish for rare and progressive chronic diseases with sparse available data. We developed an exploratory bridging model to predict premature mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f04e9f8521d549e78e4c457b63a7278e
https://hal-pasteur.archives-ouvertes.fr/pasteur-02612693
https://hal-pasteur.archives-ouvertes.fr/pasteur-02612693
Autor:
Malika Cremer, Xavier Montalban, Paul O'Connor, Ana de Vera, Philipp von Rosenstiel, Giancarlo Comi, Jack P. Antel, Ludwig Kappos, Nikolaos Sfikas
Publikováno v:
Journal of Neurology. 262:2627-2634
Fingolimod safety and efficacy data in relapsing-remitting multiple sclerosis (RRMS) are available up to 5 years, from an extension of a randomized, placebo-controlled, double-blind, phase 2 study, at a dose higher (5.0/1.25 mg) than the approved dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ee1b24fc075bc6968b42a21cea15d41
https://doi.org/10.1007/s00415-015-7834-0
https://doi.org/10.1007/s00415-015-7834-0
Autor:
Jeffrey A. Cohen, Ludwig Kappos, Shannon Ritter, Philipp von Rosenstiel, Lixin Zhang-Auberson, William Collins, Ana de Vera, Gordon Francis
Publikováno v:
Multiple Sclerosis and Related Disorders. 3:494-504
Background Fingolimod 0.5mg once daily is the first approved oral therapy for relapsing multiple sclerosis (MS). Objective To report integrated long-term safety data from phase 2/3 fingolimod studies. Methods Descriptive safety data are reported from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::964c8c88642f790b953022d6813c33cf
https://doi.org/10.1016/j.msard.2014.03.002
https://doi.org/10.1016/j.msard.2014.03.002
Autor:
Nikolaos Sfikas, Remko de Jong, Ana de Vera, Gordon Francis, Jeffrey A. Cohen, Frederik Barkhof
Publikováno v:
Barkhof, F, Jong, R, Sfikas, N, de Vera, A, Francis, G & Cohen, J 2014, ' The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis ', Multiple Sclerosis, vol. 20, no. 13, pp. 1704-1713 . https://doi.org/10.1177/1352458514532317
Multiple Sclerosis, 20(13), 1704-1713. SAGE Publications Ltd
Multiple Sclerosis, 20(13), 1704-1713. SAGE Publications Ltd
Background: Patients with multiple sclerosis (MS) lose brain volume (BV) faster than healthy individuals. Objective: Our purpose, within the 12-month phase 3 TRANSFORMS study, was to examine the effect of treatment on BV loss in patient subgroups, es
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db404a27b00db1dd0251fcfe7b31ac24
https://doi.org/10.1177/1352458514532317
https://doi.org/10.1177/1352458514532317
Autor:
Ludwig Kappos, Giancarlo Comi, Malika Cremer, Xavier Montalban, Paul O'Connor, Ana de Vera, Jack P. Antel, Nikolaos Sfikas
Publikováno v:
Neurology. 78:P01.129-P01.129
Objective: To report long-term outcomes and safety of fingolimod in relapsing multiple sclerosis (RMS) patients participating in a phase 2 study. Background After the 6-month (M) placebo controlled study in which fingolimod (1.25mg and 5mg dose group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be398b6e9af72495f7ca122193a2420f
https://doi.org/10.1212/wnl.78.1_meetingabstracts.p01.129
https://doi.org/10.1212/wnl.78.1_meetingabstracts.p01.129
Autor:
Cohen, J, Barkhof, F, Comi, G, Hartung, H, Khatri, B, Montalban, X, Pelletier, J, Capra, R, Gallo, P, Izquierdo, G, Tiel Wilck, K, de Vera, A, Jin, J, Stites, T, Wu, S, Aradhye, S, Kappos, L, TRANSFORMS Study Group, Contributor, Centonze, D
Publikováno v:
Cohen, J A, Barkhof, F, Comi, G, Hartung, H P, Khatri, B O, Montalban, X, Pelletier, J, Capra, R, Gallo, P, Izquierdo, G, Tiel-Wilck, K, de Vera, A, Jin, J, Stites, T, Wu, S, Aradhye, S & Kappos, L 2010, ' Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis ', New England Journal of Medicine, vol. 362, no. 5, pp. 402-415 . https://doi.org/10.1056/NEJMoa0907839
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2010, 362 (5), pp.402-415
New England Journal of Medicine, Vol. 362, no.5, p. 402-15 (février 2010)
New England Journal of Medicine, 2010, 362 (5), pp.402-415
New England Journal of Medicine, 362(5), 402-415. Massachussetts Medical Society
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2010, 362 (5), pp.402-415
New England Journal of Medicine, Vol. 362, no.5, p. 402-15 (février 2010)
New England Journal of Medicine, 2010, 362 (5), pp.402-415
New England Journal of Medicine, 362(5), 402-415. Massachussetts Medical Society
1533-4406 (Electronic) 0028-4793 (Linking) Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't; BACKGROUND: Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d984280e2c1921b91d36d44e8f139936